FDA Fast Track Designation for iSCIB1+

Summary by AI BETAClose X

Scancell Holdings plc has received FDA Fast Track designation for its ImmunoBody® iSCIB1+ in advanced melanoma, a significant development for the company. Data from the SCOPE Phase 2 study shows a potent and durable progression-free survival (PFS) of 77% at 20 months for iSCIB1+ in combination with ipilimumab and nivolumab, representing a 30+ percentage point improvement over standard of care. The company anticipates initiating a global registrational Phase 3 trial in the second half of 2026, with further PFS and early overall survival data expected in the first half of 2027.

Disclaimer*

UK 100

Latest directors dealings